CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on March 27, 2024
FIBROBIOLOGICS, INC.
455 E. Medical Center Blvd.
Suite 300
Houston, Texas 77598
March 27, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attention: |
Jimmy (CF) McNamara Laura Crotty |
| RE: | FibroBiologics, Inc. (the “Company”) | |
| Registration Statement on Form S-1 | ||
| File No. 333-277019 |
Dear Mr. McNamara and Ms. Crotty:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-277019) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on March 28, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.
We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| FibroBiologics, Inc. | ||
| By: | /s/ Pete O’Heeron | |
| Name: | Pete O’Heeron | |
| Title: | Chief Executive Officer | |